# Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB

> **NCT01218217** · PHASE2 · COMPLETED · sponsor: **Michael Hoelscher** · enrollment: 90 (actual)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** SQ109
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT01218217
- **Lead sponsor:** Michael Hoelscher
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-09
- **Final completion:** 2012-05
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2013-01-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218217, "Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01218217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*